Octapharma AG products

Human coagulation factor VIII produced in a human cell line by recombinant DNA technology. No animal or human derived materials are added during the manufacturing process or to the final medicinal product.

Plasma-derived human factor IX concentrate.

Contains von Willebrand factor and factor VIII in a 1:1 activity ratio. Indication: Indicated for the prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) alone is ineffective or contra-indicated, and for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).